- The stock price of Solid Biosciences Inc (NASDAQ: SLDB) increased by over 14% during intraday trading today. This is why it happened.
The stock price of Solid Biosciences Inc (NASDAQ: SLDB) – a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne) – increased by over 14% during intraday trading today. Investors are responding positively to Solid Biosciences announcing the presentation of long-term data from Patients 4-6 in the ongoing IGNITE DMD Phase I/II clinical trial of SGT-001 in patients with Duchenne. Vamshi Rao, MD, Attending Physician, Neurology, Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics (Neurology and Epilepsy), Northwestern University Feinberg School of Medicine, and an IGNITE DMD clinical investigator, will present the data on September 23, 2021, in an oral session at the World Muscle Society 2021 Virtual Congress, which is taking place September 20-24.
The presentation is going to be available to individuals registered to attend the World Muscle Society 2021 Virtual Congress.
These are the presentation details:
Title: IGNITE DMD Phase I/II ascending dose study of SGT-001 microdystrophin gene therapy for DMD: Update on long-term outcomes
Presenter: Dr. Vamshi Rao
Presentation Type: Oral presentation
Abstract Number: O.2
Presentation Time: September 23, 2021, 9:00am ET
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
